Amantadine in ASD: 10-week randomized double blind trial

Discuss autism theories, media stories, and efforts to put ASD on the government agenda here.

Moderator: ModeratorBill

Forum rules
Please limit quotes from articles to five paragraphs. Also, researchers may post study information here.
kulkulkan
Posts: 2075
Joined: Tue Mar 13, 2012 1:37 pm

Amantadine in ASD: 10-week randomized double blind trial

Postby kulkulkan » Mon Nov 11, 2013 4:50 pm

Amantadine is an anti-viral drug - however, exact mechanism of action is unknown and from wiki, "The drug has many effects in the brain, including release of dopamine and norepinephrine from nerve endings. It appears to be a weak NMDA receptor antagonist as well as an anticholinergic, specifically a nicotinic alpha-7 antagonist like the similar pharmaceutical memantine". It is used off-label for Parkinson.

Clin Neuropharmacol. 2013 Nov 5. [Epub ahead of print]
Double-Blind, Placebo-Controlled Trial of Risperidone Plus Amantadine in Children With Autism: A 10-Week Randomized Study.
Mohammadi MR, Yadegari N, Hassanzadeh E, Farokhnia M, Yekehtaz H, Mirshafiee O, Akhondzadeh S.
Source
Psychiatric Research Center, Roozbeh Hospital, Tehran University of Medical Sciences, Tehran, Iran.

Abstract
OBJECTIVE:
This study aimed to investigate the effect of adding amantadine to risperidone for treatment of autism.
METHODS:
Forty outpatients aged 4 to12 years, who were diagnosed with autism spectrum disorders based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision criteria, were assigned to this double-blind clinical trial. The subjects were divided randomly into 2 groups. One group received risperidone plus amantadine, and the other group received risperidone plus placebo. The dose of risperidone was titrated between 1 and 2.0 mg/d, and the dose of amantadine was 100 or 150 mg/d for patients less than 30 kg or more than 30 kg, respectively. The patients were assessed using the Aberrant Behavioral Checklist-Community (ABC-C) and adverse effects checklist as well as clinical global impression-improvement (CGI-I) at 2 checkpoints of 5-week intervals after the baseline. Informed consent was obtained from the parents of each participant.
RESULTS:
Among ABC-C subscales, Hyperactivity and Irritability showed significantly greater reduction in the amantadine group than the placebo group. There was no significant difference in adverse effects between the 2 groups. The CGI-I scores show significant improvement in the amantadine group compared to the placebo group.
CONCLUSIONS:
The present study suggests that amantadine may be a potential adjunctive treatment strategy for autism and it was generally well tolerated.

luis
Posts: 250
Joined: Thu Sep 25, 2008 8:42 pm

Re: Amantadine in ASD: 10-week randomized double blind trial

Postby luis » Sat Jul 12, 2014 6:45 pm

Bump.

Anyone has been using Amantadine ?

jegjr
Posts: 57
Joined: Sat Feb 12, 2011 1:33 pm

Re: Amantadine in ASD: 10-week randomized double blind trial

Postby jegjr » Fri Aug 26, 2016 12:14 pm

If you ever try Amantadine for your child and decide to take him/her off of the medication, make sure that you ween them off the med by reducing the dosage weekly until completely off. Never stop the medicine suddenly; and slowly reduce the dose over time.


Return to “Autism Articles, Studies & Politics”